Biotech Marketing Agency

Picture the kickoff: four scientists at the table, explaining a mechanism. To ask the right questions, we need to already understand how a therapy moves from discovery into the pipeline, through phase 1 and 2 — and we do.

Around fifteen biotech and life science clients over twenty years taught us the vocabulary and, more importantly, when to use it.

The hardest question in this sector isn’t explaining the science — it’s articulating why yours matters when adjacent companies sound alike. That’s usually where the kickoff earns itself.

Brilliant founders, professors, researchers: experts in their field, rarely storytellers. That’s not a flaw. It’s why we exist.

The investor scans, the scientist verifies, the HCP checks the evidence. We structure story and site so each finds their layer — without flattening the science that earned your credibility.

Precision that legal and scientific review can approve, in language a first-time reader can follow.

Ninety per cent of our clients continue after the first project — some relationships run past ten years. In a sector where the story changes per phase, that continuity pays: we already know the pipeline when the next milestone lands.

A biotech marketing agency helps biotech companies get understood by the people who matter: investors, partners, scientists, regulators and talent. The work spans strategy, branding, website, content and findability — with one requirement generic agencies miss: the science has to stay intact.

The test of good biotech marketing isn’t whether it sounds exciting. It’s whether the expert recognises the depth and the non-expert follows the story.

Because the failure mode is predictable: the science gets flattened into claims, the critical reader stops trusting the site, and the internal team spends months correcting copy.

A sector-specialised partner picks up the field fast enough to write with your scientists instead of around them. Twenty years in biotech and life sciences means fewer questions upfront and no trust destroyed in translation.

Work as due diligence material. Before a term sheet, around a milestone, after a publication — the website gets read by people deciding whether to believe you.

That means: credibility first (team, science, proof), clarity throughout (an investor should grasp the platform in one visit), and depth on demand (the scientist who wants to verify can).

We understand it fast — that’s the honest version. Our clients’ fields range from therapeutics to platforms to tools, and what twenty years in the sector gives us is the ability to pick up a new mechanism, pipeline or technology quickly and ask the right questions.

Your scientists stay the experts. Our job is making their precision readable.

Yes, and the work differs per stage. Early-stage: a brand and site that make the vision credible on a lean budget. Growth-stage: communication that keeps up as the story changes. Clinical-stage: the credibility layer that partners and investors expect.

What doesn’t change: we scale the deliverables to the phase, never the strategic work underneath.

An identity that holds from deck to website to conference: logo, typography, colour and tone designed as a system, documented in guidelines your team can use.

In biotech the bar is specific: the brand has to look credible to an investor and honest to a scientist at the same time. Overpromise visually and you lose the second reader.

Yes — findability is part of the work, not an add-on. Content that answers what your audiences actually search, on pages that are technically sound, with authority that compounds in a niche.

And increasingly: findability in AI answers, because investors ask ChatGPT before they ask you. We structure and measure for that explicitly.

That depends on scope, stage and the depth of the content work. Early in the conversation we share an estimate per phase, so you see what each part costs before it begins.

We’d rather help you spend the budget where it makes a difference this phase than push the most expensive version of the work.

Yes — a substantial part of our client base is in the US and the UK, alongside Europe. We work from Amsterdam through shared Slack and biweekly calls, in a process built for time zones years ago.

In practice, US clients rarely see us in person. The work doesn’t suffer for it; picking up your field quickly matters far more than sharing a postcode.

A brand identity typically runs six to ten weeks; a full brand-plus-website project ten to sixteen. Timelines are planned per phase upfront — and we plan internal decision-making in from day one, because that’s where biotech projects usually slow down.

Three things.

One: twenty years and more than three hundred websites and brands, a substantial share of them in knowledge-intensive fields like this one. We pick up your field fast, and we know which communication survives a critical reader and which doesn’t.

Two: strategy, brand, website and content in one team. No handovers where the science gets lost in translation.

Three: we build for findability in both worlds — search engines and AI answers — and we measure what actually happens.

Volume isn’t our position. Depth is.